Form 4: Atara Biotherapeutics Director Carol Gallagher Acquires 150,000 Shares of Common Stock

Director Carol Gallagher acquired 150,000 shares of Atara Biotherapeutics common stock on March 31, 2024, and also reports an additional 20,190 shares previously omitted.

Summary

• On March 31, 2024, Carol Gallagher, a director of Atara Biotherapeutics, acquired 150,000 shares of common stock.
• The acquisition was made at a price of $0 per share.
• These shares were obtained in the form of restricted stock units that will vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to continuous service.
• Following the transaction, Gallagher beneficially owns 629,608 shares of Atara Biotherapeutics.
• The report also includes an additional 20,190 shares that were previously inadvertently omitted from the Reporting Person's aggregate beneficial ownership.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director increasing their stake in the company is generally viewed favorably, but the acquisition being in the form of restricted stock units at $0 limits the immediate impact.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.
• The correction of a previous omission ensures accurate reporting of beneficial ownership.

Future Outlook

The restricted stock units will vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's increased stake in Atara Biotherapeutics, which is common in the biotech industry as part of compensation packages.

Comparison to Industry Standards

• Director stock ownership is a common practice in publicly traded companies, especially in the biotech sector.
• Similar to other biotech companies like Gilead Sciences or Amgen, Atara Biotherapeutics uses stock-based compensation to align the interests of its directors with those of its shareholders.
• The vesting schedule of the restricted stock units is typical, often tied to continued service and company milestones.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates